European Medicines Agency Accepts Deciphera’s Marketing Authorization Application for Vimseltinib for Treatment of Patients with Tenosynovial Giant Cell Tumor (TGCT)
CAMBRIDGE, Mass., June 25, 2024 /PRNewswire/ -- ONO PHARMA USA today announced it will provide a sponsorship to Conquer Cancer®, the ASCO Foundation, with $1 million funding to advance cancer research and education.
Ono Pharmaceutical Co. Ltd. has successfully completed its previously announced tender offer to acquire all outstanding shares of common stock of U.S. biopharmaceutical company Deciphera Pharmaceuticals Inc. for $25.60 per share (total amount of approximately $2.4 billion), through its wholly-owned subsidiary, Topaz Merger Sub Inc.
Deciphera’s other bidder: Before its acquisition by Ono Pharmaceutical, Deciphera had one other bidder that offered $19.00 per share, according to a new SEC filing. In total, Deciphera reached out to 23 companies to gauge buyout interest. Ultimately, Deciphera was acquired by Ono for $25.60 per share in April. — Max Gelman
CAMBRIDGE, Mass., May 2, 2024 /PRNewswire/ -- ONO PHARMA USA today announced partnerships with LabCentral in Cambridge, Mass., and MBC BioLabs in San Francisco and San Carlos, CA to award each organization one Golden Ticket for an innovative life sciences startup company. The competition is sponsored by ONO PHARMA USA's parent company, Ono Pharmaceutical Co., Ltd. (Ono), and applications will be received through May 2024.
Japan`s Ono to buy US drugmaker Deciphera for $2.4 bln
Deciphera Pharmaceuticals to be Acquired by ONO Pharmaceutical For $2.4 Billion
Sibylla Biotech Enters a Drug Discovery Collaboration with Ono Pharmaceutical
Ono Enters into a Research Collaboration Agreement with InveniAI